{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:03Z","timestamp":1786119303945,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"DOI":"10.1097\/qai.0b013e3181c7a29d","type":"journal-article","created":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T03:32:45Z","timestamp":1266982365000},"page":"357-363","source":"Crossref","is-referenced-by-count":13,"title":["HIV\/Hepatitis C Virus\u2212Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do"],"prefix":"10.1097","volume":"53","author":[{"given":"Anu","family":"Osinusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Rasimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Proschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoll J","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Masur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Rosenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R2-10-20210131","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R3-10-20210131","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"R4-10-20210131","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R5-10-20210131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/14787210.6.3.281","article-title":"Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.","volume":"6","author":"Mallolas","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 3","key":"R6-10-20210131","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/01.aids.0000192064.09281.48","article-title":"Perspectives on HIV\/hepatitis C virus co-infection, illicit drug use and mental illness.","volume":"19","author":"Sulkowski","year":"2005","journal-title":"AIDS"},{"key":"R7-10-20210131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jinf.2005.09.007","article-title":"Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.","volume":"53","author":"Voigt","year":"2006","journal-title":"J Infect"},{"key":"R8-10-20210131","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0025-7125(05)70526-5","article-title":"Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome.","volume":"81","author":"Coyle","year":"1997","journal-title":"Med Clin North Am"},{"key":"R9-10-20210131","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/376971","article-title":"Hematologic disorders associated with hepatitis C virus infection and their management.","volume":"37","author":"Dieterich","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R10-10-20210131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin.","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"R11-10-20210131","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R12-10-20210131","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"R13-10-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-10-20210131","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients.","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"R15-10-20210131","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-10-20210131","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2174\/092986707780597907","article-title":"Interferon: cellular executioner or white knight?","volume":"14","author":"Maher","year":"2007","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"R17-10-20210131","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.jhep.2005.11.024","article-title":"Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management.","volume":"44","author":"Mauss","year":"2006","journal-title":"J Hepatol"},{"key":"R18-10-20210131","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"R19-10-20210131","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R20-10-20210131","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-alpha.","volume":"56","author":"Capuron","year":"2004","journal-title":"Biol Psychiatry"},{"key":"R21-10-20210131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2004.04.058","article-title":"Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.","volume":"365","author":"Loftis","year":"2004","journal-title":"Neurosci Lett"},{"key":"R22-10-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3171\/jns.1988.69.1.0029","article-title":"Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.","volume":"69","author":"Saris","year":"1988","journal-title":"J Neurosurg"},{"key":"R23-10-20210131","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state.","volume":"340","author":"Capuron","year":"1999","journal-title":"N Engl J Med"},{"key":"R24-10-20210131","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0033-3182(99)71208-9","article-title":"Neuropsychiatric toxicity associated with cytokine therapies.","volume":"40","author":"Lerner","year":"1999","journal-title":"Psychosomatics"},{"key":"R25-10-20210131","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdi157","article-title":"Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.","volume":"16","author":"Mohamed","year":"2005","journal-title":"Ann Oncol"},{"key":"R26-10-20210131","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum.","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"R27-10-20210131","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","article-title":"Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.","volume":"9","author":"Cuzick","year":"2008","journal-title":"Lancet Oncol"},{"key":"R28-10-20210131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","article-title":"The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans.","volume":"5","author":"Wichers","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"R29-10-20210131","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","article-title":"Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.","volume":"128","author":"Chen","year":"2005","journal-title":"Gastroenterology"},{"key":"R30-10-20210131","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/501365","article-title":"Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons.","volume":"193","author":"Lempicki","year":"2006","journal-title":"J Infect Dis"},{"key":"R31-10-20210131","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/apc.2006.20.612","article-title":"Predictors for hematopoietic growth factors use in HIV\/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.","volume":"20","author":"Pau","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"R32-10-20210131","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/00002030-200409030-00009","article-title":"Serious ophthalmic pathology compromising vision in HCV\/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.","volume":"18","author":"Farel","year":"2004","journal-title":"AIDS"},{"key":"R33-10-20210131","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1572-0241.1998.00701.x","article-title":"Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.","volume":"93","author":"Sugano","year":"1998","journal-title":"Am J Gastroenterol"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201003010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:48Z","timestamp":1786040028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201003010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181c7a29d","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}